Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
Maria Rosario(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Walter Reinisch(Medical University of Vienna), Marc R. Gastonguay(Metrum Research Group (United States)), Adedigbo A. Fasanmade(TetraLogic Pharmaceuticals (United States)), William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Nathanael L. Dirks(Metrum Research Group (United States)), Timothy Wyant(University of Maryland, Baltimore), A. Parikh(Takeda (United States))
Cited by 266
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k